ibrutinib,obinutuzumab,venetoclax
abbvie,janssen,roche
['cll13', 'cll', 'gaia']
not only p53 or ighv status would have impact on the cll outcomes but others such as notch, braf, nras, kras based on the treatment given as demonstrated by the german group study cll13/gaia #ash22 
Guidelines, updates, Questions, Meetings in Hematology.